三维体积生长速率或为侵袭性垂体腺瘤分类提供新视角
该研究回顾性分析接受手术的生长性或增殖性垂体腺瘤患者,评估三维体积生长速率(3DVGR)与肿瘤进展及组织病理学的相关性。结果显示非增殖性与增殖性腺瘤的中位3DVGR分别为21.2%/年和60.2%/年(P < .0001),ROC分析(AUC 0.992,P < .001)定义了三组3DVGR并对应不同中位无进展生存期(PFS)。结论提出基于3DVGR的增殖分类,并认为3DVGR是结合组织学评估垂体腺瘤增殖的有价值工具。
要点
- 非增殖性与增殖性垂体腺瘤的中位3DVGR分别为21.2%/年和60.2%/年(P < .0001)。
- 3DVGR <50%/年、≥50%且<80%/年、≥80%/年的中位PFS分别为99.0、39.0和7.0个月。
- 3DVGR ≥80%/年或50%≤3DVGR<80%/年联合Ki67 ≥ 8%者中位PFS为8.5个月,其他为64个月。
核心结论
- 3DVGR或可作为评估垂体腺瘤增殖的有价值工具,与组织学联合使用。
- 垂体腺瘤增殖可按3DVGR分类:<10%/年为非和/或缓慢进展,10-49%/年为缓慢进展,50-79%/年为进展,≥80%/年为高度进展。
研究设计与样本
- 回顾性选取接受手术的生长性或增殖性垂体腺瘤患者,要求有钆增强3D T1加权MRI。
- 共对50个非增殖性和25个增殖性垂体腺瘤进行了76次3DVGR测量。
主要发现
- 非增殖性与增殖性垂体腺瘤的中位3DVGR分别为21.2%/年和60.2%/年(P < .0001)。
- ROC分析(AUC 0.992,P < .001)定义了三组3DVGR:<50%/年、≥50%且<80%/年、≥80%/年,中位PFS分别为99.0、39.0和7.0个月。
- 3DVGR <50%/年的肿瘤中,增殖状态对PFS无显著影响(P = .381);3DVGR ≥50%/年的增殖性肿瘤预后差于3DVGR <50%/年者(P < .001)。
- 多因素分析中,仅3DVGR ≥50%/年预测早期进展(P < .001),增殖状态则不然。
- 3DVGR ≥80%/年或50%≤3DVGR<80%/年联合Ki67 ≥ 8%识别出12个垂体腺瘤,中位PFS为8.5个月,其他为64个月。
关键数值与推荐
- 3DVGR分组阈值:<50%/年、≥50%且<80%/年、≥80%/年,对应中位PFS分别为99.0、39.0、7.0个月。
- 联合标准:3DVGR ≥80%/年或50%≤3DVGR<80%/年且Ki67 ≥ 8%,中位PFS为8.5个月 vs 其他64个月。
- 提出的分类:<10%/年非和/或缓慢进展,10-49%/年缓慢进展,50-79%/年进展,≥80%/年高度进展。
临床怎么用
- 在垂体腺瘤评估中可纳入3DVGR测量,辅助组织病理学判断增殖性。
- 3DVGR ≥50%/年提示早期进展风险增高,需加强随访。
- 3DVGR ≥80%/年或联合Ki67 ≥ 8%者进展风险更高,中位PFS仅8.5个月。
局限性
- 回顾性研究设计。
- 样本量有限(50个非增殖性和25个增殖性垂体腺瘤,共76次测量)。
- 需要钆增强3D T1加权MRI,可能限制推广。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The 2022 WHO classification states no histological grading exists to assess pituitary adenoma (PA) aggressiveness. The European Society of Endocrinology refers to the term "unusually rapid growth rate" when defining an aggressive PA. This study aimed to evaluate three-dimensional volume growth rate (3DVGR) in multiple PAs and correlate it with tumor progression and histopathology. METHODS: Patients with growing or proliferative PAs who underwent surgery were retrospectively selected. Gadolinium-enhanced 3D T1-weighted MRI was required. RESULTS: A total of 76 3DVGR measurements were performed on 50 nonproliferative and 25 proliferative PAs, with median 3DVGRs of 21.2%/year and 60.2%/year, respectively (P < .0001). ROC analysis (AUC 0.992, P < .001) defined three 3DVGR groups: <50%/year, ≥50%, and <80%/year, ≥80%/year with a median PFS of 99.0, 39.0, and 7.0 months, respectively. In tumors with 3DVGR <50%/year, proliferative status had no significant progression-free survival impact (P = .381). In contrast, proliferative tumors with 3DVGR ≥50%/year had worse outcomes than those with 3DVGR <50%/year (P < .001). In multivariate analysis, only 3DVGR ≥50%/year predicted early progression (P < .001), unlike proliferative status. Combining 3DVGR ≥80%/year or 50% ≤3DVGR < 80%/year with Ki67 ≥ 8% identified 12 PAs with a median PFS of 8.5 months vs 64 months in others. CONCLUSION: PA proliferation may be categorized as: <10%/year: non and/or slowly progressive, 10-49%/year: slowly progressive, 50-79%/year: progressive, ≥80%/year: highly progressive. 3DVGR appears to be a valuable tool to evaluate PA proliferation alongside histology.
引用
- Graillon T, Tabouret E, Appay R, et al. 3D volume growth rate may open new perspectives for the classification of aggressive pituitary adenomas. J Clin Endocrinol Metab. 2026. PMID: 41973981. doi:10.1210/clinem/dgag145
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。